VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice

Molecular Therapy

Volumn 8, Issue 5, 2003, Pages 840-845

  Zavaglia, David ^a   Normand, Nadia ^b   Brewis, Neil ^b   O'Hare, Peter ^b   Favrot, Marie Christine ^a   Coll, Jean Luc ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Antisense; In vivo; Nonviral delivery; Photodynamic; Protein transduction; VP22

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORESCENT DYE; PROTEIN VP22; RAF PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; ILLUMINATION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PHOTODYNAMICS; PHOTOSTIMULATION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE;

ANIMALIA; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0348133556     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.08.001     Document Type: Article

References (17)

1. Watson, J. D., and Crick, F. H. (1974). Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 248: 765 [Republication].
2. Tamm, I., Dorken, B., and Hartmann, G. (2001). Antisense therapy in oncology: new hope for an old idea? Lancet 358: 489-497.
3. Elliott, G., and O'Hare, P. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88: 223-233.
4. Phelan, A., Elliott, G., and O'Hare, P. (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16: 440-443.
5. Zender, L., et al. (2002). Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 123: 608-618.
6. Dilber, M. S., et al. (1999). Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 6: 12-21.
7. Wybranietz, W. A., et al. (2001). Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther. 8: 1654-1664.
8. Zavaglia, D., Favrot, M., Eymin, B., Tenaud, C., and Coll, J. (2003). Intercellular trafficking and enhanced in vivo antitumor activity of a non-virally delivered P27-VP22 fusion protein. Gene Ther. 10: 314-325.
9. Normand, N., van Leeuwen, H., and O'Hare, P. (2001). Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276: 15042-15050.
10. Brewis, N. D., Phelan, A., Normand, N., Choolun, E., and O'Hare, P. (2003). Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis. Mol. Ther. 7: 262-270.
11. Lau, Q. C., Brusselbach, S., and Muller, R. (1998). Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 16: 1899-1902.
12. Sciortino, M. T., Taddeo, B., Poon, A. P., Mastino, A., and Roizman, B. (2002). Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc. Natl. Acad. Sci. USA 99: 8318-8323.
13. Koelle, D. M., Frank, J. M., Johnson, M. L., and Kwok, W. W. (1998). Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 72: 7476-7483.
14. Koelle, D. M., Schomogyi, M., McClurkan, C., Reymond, S. N., and Chen, H. B. (2000). CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J. Virol. 74: 11422-11425.
15. Monia, B. P., et al. (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93: 15481-15484.
16. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. (1996). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2: 668-675.
17. Carthew, R. W. (2001). Gene silencing by double-stranded RNA. Curr. Opin. Cell Biol. 13: 244-248.